BNP Paribas Asset Management
INDV icon

BNP Paribas Asset Management’s Indivior Pharmaceuticals INDV Stock Holding History

BNP Paribas Asset Management’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.88M Buy
94,458
+66,189
+234% +$2.4M ﹤0.01% 961
2026
Q1 		$862K Sell
28,269
-82,079
-74% -$2.71M ﹤0.01% 1188
2025
Q4 		$3.96M Buy
+110,348
New +$3.37M ﹤0.01% 897

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BNP Paribas Asset Management's INDV Position: Q2 2026 in Review

BNP Paribas Asset Management increased its Indivior Pharmaceuticals (INDV) stake by 234% in Q2 2026, buying an estimated $2.4M and bringing the position to 94,458 shares worth $3.88M. The position accounts for ﹤0.01% of the portfolio, ranked #961.

BNP Paribas Asset Management first reported a position in INDV in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.96M in Q4 2025. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • BNP Paribas Asset Management held 94,458 shares of Indivior Pharmaceuticals worth $3.88M as of Q2 2026.
  • BNP Paribas Asset Management bought 66,189 Indivior Pharmaceuticals shares in Q2 2026, an estimated $2.4M.
  • Indivior Pharmaceuticals made up ﹤0.01% of BNP Paribas Asset Management's portfolio in Q2 2026, its #961 holding.
  • BNP Paribas Asset Management first reported a position in Indivior Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • BNP Paribas Asset Management's Indivior Pharmaceuticals position peaked at $3.96M in Q4 2025.
  • 338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.